Spruce Biosciences, Inc. Operating Expenses
Spruce Biosciences, Inc. (SPRB) reported Operating Expenses of $16.51 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-12
- Spruce Biosciences, Inc. operating expenses for the quarter ending 2026-06-30 was $16.51M, a 513.37% increase year-over-year.
- Spruce Biosciences, Inc. operating expenses for the quarter ending 2026-03-31 was $11.99M, a 17.29% decline year-over-year.
- Spruce Biosciences, Inc. operating expenses for the quarter ending 2025-12-31 was $11.10M, a 55.19% decline year-over-year.
- Spruce Biosciences, Inc. operating expenses for the quarter ending 2025-09-30 was $8.23M, a 17.79% decline year-over-year.
- Spruce Biosciences, Inc. operating expenses for fiscal 2025 was $36.51M, a 40.20% decline from fiscal 2024.
- Spruce Biosciences, Inc. operating expenses for fiscal 2024 was $61.06M, a 1.64% decline from fiscal 2023.
- Spruce Biosciences, Inc. operating expenses for fiscal 2023 was $62.08M, a 31.30% increase from fiscal 2022.
- Spruce Biosciences, Inc. operating expenses for fiscal 2022 was $47.28M, a 12.40% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.51M 10-Q · filed 2026-08-12 | $28.50M 10-Q · filed 2026-08-12 | $39.60M derived: sum of 3 quarters · filed 2026-08-12 | $47.83M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $11.99M 10-Q · filed 2026-05-13 | $23.09M derived: sum of 2 quarters · filed 2026-05-13 | $31.32M derived: sum of 3 quarters · filed 2026-05-13 | $34.01M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $11.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $19.33M derived: sum of 2 quarters · filed 2026-03-09 | $22.02M derived: sum of 3 quarters · filed 2026-08-12 | $36.51M 10-K · filed 2026-03-09 |
| 2025-09-30 | $8.23M 10-Q · filed 2025-11-10 | $10.92M derived: sum of 2 quarters · filed 2026-08-12 | $25.41M 10-Q · filed 2025-11-10 | $50.18M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $2.69M 10-Q · filed 2026-08-12 | $17.18M 10-Q · filed 2026-08-12 | $41.95M derived: sum of 3 quarters · filed 2026-08-12 | $51.97M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $14.49M 10-Q · filed 2026-05-13 | $39.26M derived: sum of 2 quarters · filed 2026-05-13 | $49.27M derived: sum of 3 quarters · filed 2026-05-13 | $60.92M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $24.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $34.78M derived: sum of 2 quarters · filed 2026-03-09 | $46.43M derived: sum of 3 quarters · filed 2026-03-09 | $61.06M 10-K · filed 2026-03-09 |
| 2024-09-30 | $10.01M 10-Q · filed 2025-11-10 | $21.66M derived: sum of 2 quarters · filed 2025-11-10 | $36.29M 10-Q · filed 2025-11-10 | $50.34M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $11.65M 10-Q · filed 2025-08-14 | $26.28M 10-Q · filed 2025-08-14 | $40.33M derived: sum of 3 quarters · filed 2025-08-14 | $57.06M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $14.63M 10-Q · filed 2025-05-06 | $28.69M derived: sum of 2 quarters · filed 2025-05-06 | $45.42M derived: sum of 3 quarters · filed 2025-05-06 | $61.55M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $14.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $30.78M derived: sum of 2 quarters · filed 2025-04-15 | $46.92M derived: sum of 3 quarters · filed 2025-04-15 | $62.08M 10-K · filed 2025-04-15 |
| 2023-09-30 | $16.73M 10-Q · filed 2024-11-12 | $32.87M derived: sum of 2 quarters · filed 2024-11-12 | $48.03M 10-Q · filed 2024-11-12 | $60.14M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $16.14M 10-Q · filed 2024-08-12 | $31.30M 10-Q · filed 2024-08-12 | $43.41M derived: sum of 3 quarters · filed 2024-08-12 | $54.97M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $15.16M 10-Q · filed 2024-05-13 | $27.27M derived: sum of 2 quarters · filed 2024-05-13 | $38.83M derived: sum of 3 quarters · filed 2024-05-13 | $50.71M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $12.11M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $23.67M derived: sum of 2 quarters · filed 2024-03-18 | $35.55M derived: sum of 3 quarters · filed 2024-03-18 | $47.28M 10-K · filed 2024-03-18 |
| 2022-09-30 | $11.56M 10-Q · filed 2023-11-13 | $23.44M derived: sum of 2 quarters · filed 2023-11-13 | $35.17M 10-Q · filed 2023-11-13 | $44.31M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $11.88M 10-Q · filed 2023-08-14 | $23.62M 10-Q · filed 2023-08-14 | $32.75M derived: sum of 3 quarters · filed 2023-08-14 | $44.15M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $11.73M 10-Q · filed 2023-05-15 | $20.87M derived: sum of 2 quarters · filed 2023-05-15 | $32.27M derived: sum of 3 quarters · filed 2023-05-15 | $43.98M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $9.13M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $20.54M derived: sum of 2 quarters · filed 2023-03-16 | $32.25M derived: sum of 3 quarters · filed 2023-03-16 | $42.07M 10-K · filed 2023-03-16 |
| 2021-09-30 | $11.40M 10-Q · filed 2022-11-10 | $23.11M derived: sum of 2 quarters · filed 2022-11-10 | $32.93M 10-Q · filed 2022-11-10 | $41.27M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $11.71M 10-Q · filed 2022-08-10 | $21.53M 10-Q · filed 2022-08-10 | $29.87M derived: sum of 3 quarters · filed 2022-08-10 | $39.42M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $9.82M 10-Q · filed 2022-05-11 | $18.15M derived: sum of 2 quarters · filed 2022-05-11 | $27.71M derived: sum of 3 quarters · filed 2022-05-11 | $34.10M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $8.34M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $17.89M derived: sum of 2 quarters · filed 2022-03-14 | $24.28M derived: sum of 3 quarters · filed 2022-03-14 | $29.42M 10-K · filed 2022-03-14 |
| 2020-09-30 | $9.56M 10-Q · filed 2021-11-15 | $15.95M derived: sum of 2 quarters · filed 2021-11-15 | $21.08M 10-Q · filed 2021-11-15 | $24.21M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $6.39M 10-Q · filed 2021-08-10 | $11.52M 10-Q · filed 2021-08-10 | $14.66M derived: sum of 3 quarters · filed 2021-08-10 | $17.22M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $5.13M 10-Q · filed 2021-05-12 | $8.27M derived: sum of 2 quarters · filed 2021-05-12 | $10.83M derived: sum of 3 quarters · filed 2021-05-12 | |
| 2019-12-31 | $3.13M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-22 | $5.70M derived: sum of 2 quarters · filed 2021-03-22 | $13.11M 10-K · filed 2021-03-22 | |
| 2019-09-30 | $2.56M 10-Q · filed 2020-11-18 | $9.97M 10-Q · filed 2020-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |